Optimal children’s eye health will require summer outdoor activities, less near work and regular check-ins. TORONTO--(BUSINESS WIRE)--While the horizon of a return to normal seems less distant, a new survey by CooperVision Canada and Maru/Blue1 suggest
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on psychedelic pharmaceutical therapies, is pleased to announce that Adelia Therapeutics Inc. (“Adelia”), a wholly-contro
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today released financial and business highlights for its financial year ended March
Agreement includes commercializing biosimilar candidate of ophthalmology drug ranibizumab (Lucentis®) in Europe, Canada, Israel and global markets TEL AVIV, Israel & ZURICH--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and
LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced that it has entered into an exclu
Strong fit with strategy to serve high-growth sustainable end markets of agritech and industrial water treatment Enhances digital connectivity to Dosatron® smart dosing pump system in Precision and Science Technologies Segment (PST) to improve dosing
- Phase III-enabling activities for otenaproxesul proceeding well; AME study begins next week - Ended year with a strong $72 million cash position, providing over two years of runway and fully funding Phase III adaptive trial TORONTO--(BUSINESS WIRE)--A
LAS VEGAS & TORONTO--(BUSINESS WIRE)--Flower One Holdings Inc. ("Flower One" or the "Company") (CSE: FONE) (OTCQX: FLOOF) (FSE: F11), the leading cannabis cultivator and producer in Nevada, today provides its fifth bi-weekly status report further to the C
TORONTO--(BUSINESS WIRE)--Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (“Greenbrook” or the “Company”) today announced that it has elected to withdraw its previously announced public offering of common shares (the “Offering”). In light of mar
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will participate in a v
BAM's 2023 Most Promising Bioscience Student, Daniel Gussakovsky, and recent scholarship winner, shares about his research, why he's chosen it, and what he hopes to do in the future with it.
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.